Clinical Trial Examines Gene Therapy for Dialysis Patients

May 19, 2010
Timmy Lee, MD

(PhysOrg.com) -- A new gene therapy may help sustain dialysis access in patients, eliminating the need for multiple interventions and surgeries and improving their quality of life.

Timmy Lee, MD, UC Health nephrologist, and Rino Munda, MD, UC Health transplant surgeon, are leading a local branch of a national clinical trial looking at the product Trinam to see if it prevents stenosis, or narrowing of the veins at the connection of the vein and dialysis graft, in .

"Trinam is a combination of a vascular endothelial growth factor gene—a protein produced by cells that stimulates to dilate and prevents formation of blockages—packaged in an adenoviral vector—or virus—which delivers into cells,” says Lee, the lead investigator on the study. "We hope that this treatment will lead to more successful outcomes for .”

Hemodialysis is a technique in which a machine filters wastes out of a patient’s blood once the kidney fails but requires access to the patient’s .

There are over 450,000 people undergoing hemodialysis in the United States, a process that costs taxpayers a minimum of $60,000 per patient annually.

Lee says there are two main types of permanent dialysis access: an arteriovenous fistula, which connects the artery and the vein directly, and an arteriovenous graft, which connects the artery and the vein using a plastic tube.

Unfortunately, grafts may only last between six and 12 months due to stenosis before requiring an intervention.

As a result, hemodialysis patients often have repeated hospital admissions and surgeries in order to keep their dialysis access open.

"Using this treatment, Trinam will be delivered locally to the dialysis access areas of approximately 250 subjects using a biodegradable device made from ,” Lee says. "At the end of access graft surgery, the delivery device is fitted around the outside of the patient's vein where it has been joined to the access graft and the adenovirus carrying the gene product is injected between the device and the blood vessel.

"We believe that the genetic material in Trinam will stimulate the relaxation of the muscle and disburse the medications that will help keep the vein open and functioning.”

He adds that local delivery may be more effective than other medicines because it is applied directly to the site where the stenosis most commonly occurs.

"It immediately stimulates the appropriate regulators right at the site of the problem, avoiding side effects that may accompany the metabolism of other medicines in body,” he says. "We hope that this therapy will improve the quality of care for patients undergoing dialysis and will prevent the need for surgeries and invasive procedures to keep dialysis access open.”

The local study is being conducted as a research initiative of the Cincinnati Dialysis Access Program (CAP) and UC’s division of nephrology and hypertension. The CAP is a multi-disciplinary translational research program focused on both the basic science and clinical research aspects of dialysis access dysfunction. Ark Therapeutics is sponsoring the trial.

Related Stories

Recommended for you

Key discoveries offer significant hope of reversing antibiotic resistance

October 23, 2017
Resistance to antibiotics is becoming increasingly prevalent and threatens to undermine healthcare systems across the globe. Antibiotics including penicillins, cephalosporins and carbapenems are known as β-lactams and are ...

Novel therapies for multidrug-resistant bacteria

October 23, 2017
During this innovative study published in PLOS One, researchers found that novel classes of compounds, such as metal-complexes, can be used as alternatives to or to supplement traditional antibiotics, which have become ineffective ...

Exploring how herpes simplex virus changes when passed between family members

October 22, 2017
A new study explores how herpes simplex virus might change when passed from one individual to another, information that may prove useful in future development of therapeutics and vaccines. This rare glimpse into a transmission ...

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

Migraines may be the brain's way of dealing with oxidative stress

October 19, 2017
A new perspective article highlights a compelling theory about migraine attacks: that they are an integrated mechanism by which the brain protects and repairs itself. Recent insightful findings and potential ways to use them ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.